Showing results (211-220 of 237) with videos related to

Sort By:
Pageof 24
The Lancet. Oncology|November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialUwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 2, 2019
Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell TransplantationNico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, et al.
Blood|January 15, 2025
Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemiaJulian Ronnacker, Michael Grau, Maximilian Klasmeier, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 19, 2023
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapyConrad-Amadeus Voltin, Andrea Paccagnella, Michael Winkelmann, et al.
Blood|December 28, 2023
Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALLLorenz Bastian, Thomas Beder, Malwine J Barz, et al.
Bone Marrow Transplantation|November 18, 2023
Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantationAlexandros Spyridonidis, Myriam Labopin, Tobias Gedde-Dahl, et al.
Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Bone Marrow Transplantation|September 10, 2025
Improved GVHD-free relapse-free survival when rATG/ATLG is used in allo-HCT from matched sibling donors - an EBMT registry study by the Transplant Complications Working PartyAgnieszka Piekarska, Mouad Abouqateb, William Boreland, et al.
Haematologica|August 8, 2024
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III studyDietger Niederwieser, Dirk Hasenclever, Wolfgang E Berdel, et al.
Blood|March 27, 2025
Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosisJuan Carlos Hernandez-Boluda, Adrian Mosquera Orgueira, Luuk Gras, et al.
Pageof 24